http://orcid.org/0000-0002-6042-779X
Figures & data
Figure 1. Flowchart showing the inclusion and exclusion of patients registered in the Danish Pancreatic Cancer Database (DPCD) from 2011–2016. The histopathological data for 72 patients were reviewed due to the missing status of the data in the DPCD. *Data shown in the Supplement Table 1. GemPac: Gemcitabine and nab-paclitaxel; FOLFIRINOX: 5-Fluorouracil, leucovorin, irinotecan and oxaliplatin; GemCap: Gemcitabine and capecitabine; GemS1: Gemcitabine and tegafur/gimeracil/oteracil.
Table 1. Comparison of the variables between patients receiving (CT group) or not receiving (NCT group) postoperative gemcitabine within 10 weeks after resection (landmark of 10 weeks).
Figure 2. OS at the landmark of 10 weeks according to patients receiving (CT group) or not receiving (NCT group) postoperative gemcitabine within 10 weeks after resection.
Table 2. Median OS according to postoperative gemcitabine treatment (CT group) or no treatment (NCT group) within 10 weeks after resection in all patients and in the subgroups with and without lymph node metastases, as well as the OS for all patients at 1, 3, and 5 years of follow-up (landmark of 10 weeks).
Table 3. Univariate and multivariate Cox regression analyses of the prognostic factors associated with survival (landmark of 10 weeks).
Figure 3. OS according to patients who received gemcitabine <22 weeks (incomplete treatment) or ≥22 weeks (complete treatment) at the landmark of 32 weeks. Gem: Gemcitabine.
